Novo Nordisk

Novo Nordisk Shares Gain 2.4% Following Additional CagriSema Weight-Loss Trial Analyses

Novo Nordisk (NYSE:NVO) shares rose 2.4% after the Danish pharmaceutical company presented additional findings from its REDEFINE 1 clinical trial, showing that participants who responded early to its experimental obesity treatment CagriSema achieved average weight loss of 25.4% after 68 weeks.

The findings, presented at ObesityWeek 2026, examined differences in weight-loss outcomes between participants who responded to treatment within the first eight weeks and those whose initial response was slower.

According to Novo Nordisk, 67.8% of participants receiving CagriSema lost at least 5% of their body weight during the first eight weeks of treatment.

Among these early responders, average weight loss reached 25.4% at week 68, compared with 17.8% among participants who did not achieve the same initial weight-loss threshold.

CagriSema Combines Two Hormone-Based Treatments

CagriSema is an investigational once-weekly injectable treatment combining cagrilintide and semaglutide, two medicines designed to mimic hormones involved in appetite regulation.

The REDEFINE 1 trial enrolled adults living with obesity or overweight accompanied by related health conditions. Participants with type 2 diabetes were excluded from the study.

The additional analysis examined whether weight loss during the initial stages of treatment was associated with differences in longer-term outcomes.

Novo Nordisk emphasised that the findings were derived from exploratory analyses conducted after the trial rather than from new confirmatory assessments of the treatment’s effectiveness.

Consequently, the results provide additional information about observed responses within the study population but do not establish a definitive relationship between early weight loss and subsequent treatment outcomes.

Participants Report Improvements in Physical Activities and Wellbeing

A separate analysis of participant questionnaires examined changes in everyday physical functioning and aspects of personal wellbeing.

Among those receiving CagriSema, 73.1% reported meaningful improvements in their ability to perform everyday physical activities, compared with 49.1% of participants receiving placebo.

Improvements relating to self-esteem and comfort in social situations were reported by 69% of CagriSema recipients, compared with 42.1% in the placebo group.

These findings were based on participants’ reported experiences and formed part of the additional analyses presented by the company.

Gastrointestinal Side Effects Reported More Frequently With CagriSema

The analyses also provided information about adverse events and treatment discontinuation.

Gastrointestinal side effects were reported by 79.6% of participants receiving CagriSema, compared with 39.9% of those receiving placebo.

Treatment discontinuation due to adverse events occurred in 5.9% of CagriSema recipients and 3.5% of placebo recipients.

The figures indicate a higher incidence of digestive side effects among participants receiving the investigational treatment.

US Regulatory Decision Expected in Fourth Quarter of 2026

Novo Nordisk said it expects a US regulatory decision concerning CagriSema during the fourth quarter of 2026.

The treatment remains investigational and has not received regulatory approval in the United States.

The company has presented the additional REDEFINE 1 analyses as supplementary information on treatment outcomes, patient-reported improvements and tolerability ahead of the anticipated regulatory decision.

Novo Nordisk stock price


Posted

in

by

Tags: